Organon & Co (OGN)
16.84
-1.23
(-6.81%)
USD |
NYSE |
Nov 04, 13:08
Organon Debt to Equity Ratio: 17.75 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2024 | 17.75 |
| June 30, 2024 | 60.11 |
| March 31, 2024 | 181.54 |
| December 31, 2023 | -125.14 |
| September 30, 2023 | -14.69 |
| June 30, 2023 | -15.73 |
| March 31, 2023 | -11.82 |
| December 31, 2022 | -9.992 |
| Date | Value |
|---|---|
| September 30, 2022 | -8.160 |
| June 30, 2022 | -7.822 |
| March 31, 2022 | -7.275 |
| December 31, 2021 | -6.057 |
| September 30, 2021 | -5.747 |
| June 30, 2021 | -4.834 |
| March 31, 2021 | 0.3219 |
| December 31, 2020 | 0.2441 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-125.14
Minimum
Dec 2023
181.54
Maximum
Mar 2024
2.668
Average
-6.666
Median
Debt to Equity Ratio Benchmarks
| Eli Lilly and Co | 2.185 |
| Biomarin Pharmaceutical Inc | 0.1098 |
| Cassava Sciences Inc | -- |
| Ligand Pharmaceuticals Inc | 0.00 |
| TG Therapeutics Inc | 0.5775 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 12.75B |
| Total Liabilities (Quarterly) | 12.26B |
| Shareholders Equity (Quarterly) | 493.00M |
| Current Ratio | 1.705 |
| Net Debt Paydown Yield | -0.08% |